Navigation Links
Top-Line Efficacy Data Presented from Phase 2 Trial of Alemtuzumab in Multiple Sclerosis
Date:10/15/2007

of the call will be available until 9:29 p.m. on October 22, 2007.

This press release contains forward-looking statements, including statements about timelines for obtaining and presenting clinical trial data, the expected efficacy of alemtuzumab in MS and its comparison to current market products, the possibility of approval of alemtuzumab in MS, and the continued enrollment of patients in related MS clinical trials. These statements are subject to risks and uncertainties that could cause actual results to differ materially from those projected in these forward-looking statements. These risks and uncertainties include, among others, that actual results of the clinical trials demonstrate safety and efficacy comparable to the data that have emerged to date, the actual timing and content of submissions to and decisions made by the regulatory authorities, institutional review boards, data safety monitoring boards and treating physicians regarding the continued administration of alemtuzumab to MS patients, Genzyme's ability to develop and obtain approval of a patient safety plan, and the other risks and uncertainties described in reports filed by Genzyme with the Securities and Exchange Commission under the Securities Exchange Act of 1934, as amended, including without limitation the information under the heading "Risk Factors" in the Management's Discussion and Analysis of Financial Condition and Results of Operations section of the Genzyme Quarterly Report on Form 10-Q for the quarter ending June 30, 2007. Genzyme cautions investors not to place substantial reliance on the forward-looking statements contained in this press release. These statements speak only as of the date of this press release, and Genzyme undertakes no obligation to update or revise the statements.

Genzyme and Campath(R) and MabCampath(R) are registered trademarks of Genzyme Corporation. Rebif(R) is a registered trademark of EMD Serono, Inc.

Genzyme's press releases and other comp
'/>"/>

SOURCE Genzyme Corporation
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Opexa Therapeutics Reports Positive Top-line Data in Phase I/II Extension Trial with Tovaxin for Multiple Sclerosis
2. Medivation to Host Conference Call to Discuss Top-Line 12-Month Results From Dimebon Alzheimers Disease Study
3. Evotec AG (DE) - Evotec Reports Positive Proof-of-Concept Top-Line Results with ...
4. Evotec Reports Positive Proof-of-Concept Top-Line Results with Insomnia Drug Candidate EVT 201
5. Peregrine Pharmaceuticals Reports Positive Top-Line Results in Bavituximab Combination Therapy Trial in Advanced Cancer Patients
6. Catalyst Pharmaceutical Partners, Inc. Announces Top-Line Results of Its Bioequivalence Study of CPP-109 (Vigabatrin), the Companys Investigational Drug to Treat Cocaine and Methamphetamine Addiction
7. Cobalis Expects to Report Phase III Top-Line Results in May
8. XenoPort Reports Positive Top-Line Phase 3 Trial Results of XP13512 in Restless Legs Syndrome
9. Amarin Reports Top-Line Results of two Phase III Studies of Miraxion in Huntingtons Disease
10. UCB Announces Positive Top-Line Phase III Results for Keppra as Adjunctive Therapy for Partial Onset Seizures in Paediatric Patients from One Month to Less than Four Years of Age
11. Opexa Therapeutics Reports Positive Top-line Data in Phase I/II Dose Escalation Trial with Tovaxin for Multiple Sclerosis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/30/2014)... 30, 2014 , Extensively hydrolyzed ... milk   Cow milk protein allergy (CMPA) is the leading ... Until now, it has been managed by eliminating milk ... shown that it is possible to help build of ... of children during the first year of life by ...
(Date:10/30/2014)... , Oct. 29, 2014 The global ... of test type, technology, product, and geography. The ... highest growth rate in the newborn screening market ... growth is attributed to various nations opting for ... fundamental instrument used for expanded newborn screening. Furthermore, ...
(Date:10/30/2014)... -- Hospital stretchers are apparatus used to transport ... or outside of medical infrastructure premises. In addition ... for several specialized functions such as hospital beds, ... The hospital stretchers market report studies the ... of hospital stretchers globally. The hospital stretchers market ...
Breaking Medicine Technology:Experts Present Latest Research at Allergy Day 2Experts Present Latest Research at Allergy Day 3NewBorn Screening Market by Test Type, Technology (Tandem Mass Spectrometry, Immunoassay, Enzyme Assay, Electrophoresis, Pulse Oximeter), Instrument, Accessories, Reagent & Assay Kit - Global Forecast to 2019 2NewBorn Screening Market by Test Type, Technology (Tandem Mass Spectrometry, Immunoassay, Enzyme Assay, Electrophoresis, Pulse Oximeter), Instrument, Accessories, Reagent & Assay Kit - Global Forecast to 2019 3Hospital Stretchers Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2013 - 2019 2Hospital Stretchers Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2013 - 2019 3
... of Directors of BD (Becton, Dickinson and Company) (NYSE: ... common share, payable on March 30, 2012 to holders of record ... per share. About BD ... develops, manufactures and sells medical devices, instrument systems and reagents. The ...
... Vystar Corporation (OTCBB: VYST), the exclusive creator of ... and first Chinese patent for its all-natural raw ... patents in the US and abroad that relate to Vytex ... http://photos.prnewswire.com/prnh/20100203/CL48049LOGO ) The new US patent ...
Cached Medicine Technology:Vystar® Corporation Receives its Third US Patent and First Chinese Patent for Vytex® Natural Rubber Latex 2Vystar® Corporation Receives its Third US Patent and First Chinese Patent for Vytex® Natural Rubber Latex 3
(Date:10/30/2014)... San Diego, Calif. (PRWEB) October 30, 2014 ... no longer mutually exclusive concepts in the medical-grade ... focusing on the development of uniquely potent topical ... Skin Health System ( http://www.RefinitySkinScience.com ) with patented ... highest available glycolic acid concentrations (50% and 70%) ...
(Date:10/30/2014)... 2014 PreDiabetes Centers , the ... shoppers with a supply of sugardown®, a chewable ... post-meal blood sugar spikes. Learning how to control blood ... part of a diabetes prevention plan. , Shoppers who ... complimentary tube of sugardown. The offer expires November 30. ...
(Date:10/30/2014)... CT (PRWEB) October 30, 2014 Radio ... are raising questions about the impact of traditional radio ... marketing method most likely to influence a purchasing decision. ... poll of 525 consumers conducted by radio marketing company ... product categories, isolating the results of respondents who indicated ...
(Date:10/30/2014)... HealthDay Reporter , WEDNESDAY, Oct. 29, ... been identified that appear linked to autism spectrum disorders, ... are on their way to discovering up to 1,000 ... Autism spectrum disorders include a range of developmental disabilities ... An estimated one in 68 U.S. children has an ...
(Date:10/30/2014)... 30, 2014 Home Care Assistance – ... of non-medical, in-home senior care, is weighing in on ... health. , The study, performed by the University of ... and 78 over a week-long period and observed how ... physical activity. By examining the structural soundness of the ...
Breaking Medicine News(10 mins):Health News:Cosmederm Redefines Peel Science Standard with Launch of Refinity® Skin Health System 2Health News:Cosmederm Redefines Peel Science Standard with Launch of Refinity® Skin Health System 3Health News:Cosmederm Redefines Peel Science Standard with Launch of Refinity® Skin Health System 4Health News:PreDiabetes Treatment Company Offers PreD Store Shoppers Supplements to Support Healthy Blood Sugar 2Health News:CRN Research On Radio Messaging Effectiveness Now Available In Four Specific Product Categories 2Health News:CRN Research On Radio Messaging Effectiveness Now Available In Four Specific Product Categories 3Health News:Discovery of 100-Plus Genes Tied to Autism May Improve Treatments 2Health News:Discovery of 100-Plus Genes Tied to Autism May Improve Treatments 3Health News:Home Care Assistance – Halton/Peel Region, a Top Provider of In-Home Care, Responds to Study Linking Exercise to Healthier Senior Brains 2Health News:Home Care Assistance – Halton/Peel Region, a Top Provider of In-Home Care, Responds to Study Linking Exercise to Healthier Senior Brains 3
... Treatment with the glitazone class of diabetes drugs leads ... macular edema (DME)a common complication that can lead to ... of the American Journal of Ophthalmology ( ... of about 170,000 patients with diabetes, Drs. Donald S. ...
... and David Glick highlight the serious issue of ... by F1000 Medicine Reports. , Consciousness during general ... post-operative psychological trauma and contributes towards patients, fear ... of 1000 Medicine and a leading authority on ...
... Be FeaturedSAN FRANCISCO, April 2 Over 1,000 cataract ... a San Francisco hotel Friday night. They will observe ... live from Key Whitman Eye Center in Dallas, Texas. ... approved accommodating Intraocular lens (IOL) in one patient and ...
... of Troy Limited (Nasdaq: HELE ), designer, ... household consumer products, today announced the March 31, 2009 ... global Infusium 23(R) hair care business from The Procter ... plus year heritage, has established a trusted reputation with ...
... Say They Will Not Provide Reimbursement for Xarelto ... Greater Convenience, According to a New Report from ... one of the world,s leading research and advisory ... for prevention of stroke, surveyed cardiologists estimate they ...
... is in the air, and along with it, tree, ... sufferer,s immune system a curve ball. But the April ... magazine uncovers five other surprising allergy ... need to be."When your immune system is weak, it ...
Cached Medicine News:Health News:Diabetes drug class linked to vision-threatening complication 2Health News:Surgeons to Observe and Discuss Live Eye Surgery Friday Night in San Francisco 2Health News:Surgeons to Observe and Discuss Live Eye Surgery Friday Night in San Francisco 3Health News:Helen of Troy Limited Announces Closing of Global Infusium Brand Acquisition From Procter & Gamble 2Health News:Helen of Troy Limited Announces Closing of Global Infusium Brand Acquisition From Procter & Gamble 3Health News:Helen of Troy Limited Announces Closing of Global Infusium Brand Acquisition From Procter & Gamble 4Health News:For Prevention of Stroke, Surveyed Cardiologists and PCPs Expect to Prescribe Xarelto to Approximately One-Third of Newly-Diagnosed Atrial Fibrillation Patients 2Health News:For Prevention of Stroke, Surveyed Cardiologists and PCPs Expect to Prescribe Xarelto to Approximately One-Third of Newly-Diagnosed Atrial Fibrillation Patients 3Health News:Surprising Allergy Triggers May Be Making Your Spring Sniffles Worse 2
... is enzyme immunoassay kit for the ... concentration in serum. Enzyme immunoassay (EIA) ... many protein hormones in body fluids ... rapid and specific assay. This enzyme ...
SHIONORIA BNP,is a reagent used in the measurement of blood BNP. The blood BNP test allows accurate estimation of coronary functions....
... method for the semi-quantitative determination of ... human serum. The results of the ... an aid in the diagnosis of ... with elevated anti-neutrophil cytoplasmic antibodies (P-ANCA) ...
... The determination of Ang ... in monitoring the pharmacological effect ... variety of angiotensin converting enzyme ... II receptor antagonists as well ...
Medicine Products: